Patients with intermediate-risk prostate cancer who can safely forgo androgen deprivation therapy (ADT) may be spared its quality-of-life effects.

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial of men with prostate cancer. Significantly more coronary artery plaque ...

If you’ve been diagnosed with advanced prostate cancer, there’s a good chance you’ll receive androgen deprivation therapy (ADT) at some point, as ADT is a mainstay of prostate cancer treatment. It ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond 9 to 12 months of ADT. HealthDay News — Increasing duration of androgen deprivation therapy (ADT) ...

Prostate cancer remains one of the most common malignancies in men worldwide, ranking as the second most prevalent cancer and ...

Metastatic Castration-Sensitive Prostate Cancer," Cleveland Clinic oncologist Christopher Wee, MD, and host John Mangels ...

The free 24-week Cancer Activity Programme (CAP), offered by Nuffield Health in partnership with NHS trusts, supports men ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

Androgen deprivation therapy plus apalutamide was significantly favored over ADT plus placebo for event-free survival. HealthDay News — Perioperative treatment with apalutamide and androgen ...

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer. The addition of apalutamide (Erleada) to androgen deprivation ...